Journals / Glokom Katarakt / 2018 / Cilt: 13 - Sayı: 2

Is Generic Dorzolamide/Timolol Fixed Combination As Effective As Original Dorzolamide/Timolol Fixed Combination?

Jenerik Dorzolamid/Timolol Fiks Kombinasyonu Orijinal Dorzolamid/Timolol Fiks Kombinasyonu Kadar Etkili Mi?

Pages
61–64
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although long term follow up is needed Oftomix can be safely used in patients for whom dorzolamide / timolol fi xed combination therapy is suitable.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the effi cacy and safety of a commonly used generic drug in ophthalmology with the original drug and to determine if the generic drug is effective.
📊
Key Findings & Data:Material and methods: Patients, newly diagnosed with open angle glaucoma and started Cosopt or Oftomix treatment between April 2016 and April 2017 in our clinic were enrolled in the study and were divided into two groups as Group A (Cosopt) and B (Oftomix) with respect to the drug they were given.
💡
Conclusion & Impact:Although long term follow up is needed Oftomix can be safely used in patients for whom dorzolamide / timolol fi xed combination therapy is suitable.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the effi cacy and safety of a commonly used generic drug in ophthalmology with the original drug and to determine if the generic drug is effective. Material and methods: Patients, newly diagnosed with open angle glaucoma and started Cosopt or Oftomix treatment between April 2016 and April 2017 in our clinic were enrolled in the study and were divided into two groups as Group A (Cosopt) and B (Oftomix) with respect to the drug they were given. Patients’ medical records before treatment and at fourth week of treatment were retrospectively evaluated. The records were also investigated for the side effects reported by the patients. Results: Twenty-fi ve eyes of 14 patients with similar demographical characteristics were enrolled. No statistically signifi cant differences were observed between the two groups with respect to intraocular pressure (IOP) values before and after treatment, the total decrease in IOP after treatment (p=0.226, p=0.688, p=0.226). In 33% of patients in Group A and in 50% of patients in Group B stinging of the eye was observed as a side effect. Other than that no local or systemic side effects were observed. With respect to those, there was no statistically signifi cant difference between the groups (p=0.75). Conclusion: The short term results for effi cacy and safety of reference original drug Cosopt and its generic drug Oftomix were found to be sim- ilar. Although long term follow up is needed Oftomix can be safely used in patients for whom dorzolamide / timolol fi xed combination therapy is suitable.

Özet

maç: Oftalmolojide yaygın kullanılan bir jenerik ilacın etkinlik ve güvenirlik açısından orijinal ilaç ile karşılaştırılması ve jenerik ilacın etkili olup olmadığının saptanması. Gereç ve Yöntemler: Nisan 2016 ve Nisan 2017 tarihleri arasında kliniğimize başvurarak yeni tanı almış, tedavisine orijinal preparat Cosopt (Merck Sharp & Dohme İlaçları Ltd.Şti.(MSD), İtalya) ve jenerik preparat Oftomix (Bilim İlaç Sanayi ve Ticaret A.Ş., Türkiye) başlanmış açık açılı glokom hastaları çalışmaya dahil edildi. Hastalar kullandıkları ilaca göre Grup A (Cosopt) ve B (Oftomix) olmak üzere iki gruba ayrıldı. Tüm hastaların ilaç başlanmadan önce ve dördüncü haftadaki muayeneleri retrospektif olarak incelendi. Kayıtlar ayrıca hastalar tarafından bildirilen yan etkiler açısından tarandı. Bulgular: Çalışmaya demografi k açıdan benzer özellikler taşıyan 14 hastanın 25 gözü dahil edildi. İki grup arası karşılaştırmada tedavi öncesi ve sonrası göz içi basıncı (GİB) değerleri ile tedavi sonrası GİB düşüş değerleri arasında istatistiksel olarak anlamlı farklılık olmadığı izlendi (sırasıyla p=0.226, p=0.688, p=0.226). Grup A’daki hastaların %33’ünde, Grup B’deki hastaların ise %50’sinde gözlerde yanma şeklinde yan etki izlendi. Bunun dışında hastalarda lokal veya sistemik yan etki izlenmedi. İki grup arasında yan etki sıklığı açısından istatistiksel olarak anlamlı farklılık olmadığı izlendi (p=0.75). Sonuç: Çalışmamızda jenerik ilaç Oftomix’in referans orijinal ilaç Cosopt ile kısa dönemdeki etkinlik ve güvenlilik sonuçlarının benzer olduğu saptanmıştır. Uzun dönem takibi gerekmekle birlikte Oftomix, dorzolamid/ timolol fi ks kombinasyon tedavisi uygun görülen hastalarda güvenle kullanılabilir.

🔖

Cite This Article

SEZENÖZ, A. S., GÜNGÖR, S. G., AKMAN, A. (2018). Is Generic Dorzolamide/Timolol Fixed Combination As Effective As Original Dorzolamide/Timolol Fixed Combination?. Glokom Katarakt, Cilt: 13 - Sayı: 2, 61–64. https://ajindex.com/articles/167553

References (9)

  1. Orijinal İlaç Nedir?. (cited 2017 August 23). Available from: URL: https://www.aifd.org.tr/yenilikcilik/orijinal-ilac-nedir/.
  2. Motola D, De Ponti F. Generic versus brand-name medicinal products: are they really interchangeable?. Dig Liver Dis 2006; 38:560–2. Frequently Asked Questions on Patents and Exclusivity. (cited 2017 August 23). Available from: URL: https://www.fda.gov/Dru- gs/DevelopmentApprovalProcess/ucm079031.htm. Aref AA. Generic drugs for the treatment ofocular conditions: changing thetreatment landscape. Expert Rev Clin Pharmacol 2014; 7: 551–3. Kahook MY. Branded vs. Generic: Proceed With Caution. Review of Ophthalmology (serial online) 2014 April (cited 2017 August 23). Available from: URL: https://www.reviewofophthalmology. com/article/branded-vs-generic-proceed-with-caution. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003; 25:2875–90. Coleman AL. Glaucoma. Lancet. 1999; 354:1803–10. Sit AJ. Intraocular pressure variations: causes and clinical signifi - cance. Can J Ophthalmol 2014; 49: 484–8.
  3. Crichton AC, Harasymowycz P, Hutnik CM et al. Effectiveness of dorzolamide- timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the CO- SOPT fi rst-line study. J Ocul Pharmacol Ther 2010; 26:503–11.
  4. Parmaksiz S, Yuksel N, Karabas VL et al. A comparison of tra- voprost, latanoprost, and the fi xed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol 2006; 16:73–80.
  5. Kim TW, Kim M, Lee EJ et al. Intraocular pressure-lowering effi - cacy of dorzolamide/ timolol fi xed combination in normal-tension glaucoma. J Glaucoma 2014; 23:329–32.
  6. Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging 2000;17:477-96.
  7. Konstas AG, Quaranta L, Yan DB et al. Twenty-four hour effi cacy with the dorzolamide/timolol-fi xed combination compared with the brimonidine/timolol-fi xed combination in primary open-angle glaucoma. Eye (Lond) 2012;26:80-7.
  8. Sezgin Akçay Bİ, Güney E, Bozkurt KT et al. The safety and effi ca- cy of brinzolamide 1%/timolol 0.5% fi xed combination versus dor- zolamide 2%/timolol 0.5% in patients with open-angle glauco- ma or ocular hypertension. J Ocul Pharmacol Ther 2013;29:882-6.
  9. Golan S, Rosenfeld E, Shemesh G et al. Original and generic lata- noprost for the treatment of glaucoma and ocular hypertension: Are they really the same